|
rs4792311
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ser217Leu and Ala541Thr variants carried no significantly elevated risk for HPC or PRCA, although the latter variant was associated with benign prostatic hyperplasia.
|
11507049 |
2001 |
|
rs5030739
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ser217Leu and Ala541Thr variants carried no significantly elevated risk for HPC or PRCA, although the latter variant was associated with benign prostatic hyperplasia.
|
11507049 |
2001 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs149709822
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
For the V89L polymorphism there were no significant differences in genotype frequencies in patients with prostate cancer and controls (p = 0.071) or in patients with BPH and male controls (p = 0.219).
|
12771801 |
2003 |
|
rs78105154
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An epidemiological study was done in sporadic PCa (n=98) and BPH (n=143) using 1 novel (Ser627Leu) and 2 previously described polymorphisms of the HPC2/ELAC2 gene.
|
12949798 |
2003 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In men with a clinical diagnosis of benign prostatic hyperplasia (BPH), polytomous logistic regression analysis was conducted to evaluate associations between two silent polymorphisms in SRD5A1 (codon positions 30 and 116), two polymorphisms in SRD5A2 (Val89Leu substitution and C to T transition in intron 1), a trinucleotide (CAG)n repeat in androgen receptor (AR), and an Arg492Cys substitution in ADRA1A and clinical parameters that characterize severity of BPH.
|
15136785 |
2004 |
|
rs1136201
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study used a case-control design to assess the predictive value of 3 polymorphisms in VDR (TaqI and FokI) and HER-2 (Val655Ile) to determine the risk of developing PRCa in patients with BPH.
|
15083213 |
2004 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Although V89L was nonsignificantly associated with BPH in overall population, BPH risk increased significantly with the number of L alleles in Hispanics (P for trend=0.03).
|
16018939 |
2005 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The A49T and TA repeat polymorphisms were not associated with BPH.
|
15389785 |
2005 |
|
rs149709822
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The A49T and TA repeat polymorphisms were not associated with BPH.
|
15389785 |
2005 |
|
rs1034866440
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs137852569
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs9332964
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs1799983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
|
16458450 |
2006 |
|
rs1800470
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the influence of the TGFB1 polymorphisms by ARMS-PCR, Leu10Pro, and Arg25Pro, on prostate cancer (PCa) and benign prostatic hyperplasia (BPH).
|
18058470 |
2007 |
|
rs1800471
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated the influence of the TGFB1 polymorphisms by ARMS-PCR, Leu10Pro, and Arg25Pro, on prostate cancer (PCa) and benign prostatic hyperplasia (BPH).
|
18058470 |
2007 |
|
rs2011077
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population.
|
18756523 |
2008 |
|
rs351855
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population.
|
18756523 |
2008 |
|
rs680055
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After considering the potential for false positive associations, the only remaining significant associations involved CYP3A43 P340A genotypes and history of BPH on both Gleason grade (interaction p-value = 0.026) and tumor stage (interaction p-value = 0.017).
|
18566991 |
2008 |
|
rs1217691063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, it has been observed that C677T polymorphism of the MTHFR gene produces no statistically significant difference for T allele frequency and the genotype frequency in prostate cancer patients and male controls with benign prostate hyperplasia not having prostate cancer, whereas it has been observed that A1298C polymorphism produces a statistically significant difference for C allele frequency in prostate cancer patients and controls and that it also produces a statistically marginal significance for genotype frequencies.
|
19814618 |
2009 |